Vemurafenib

Trade Name:
Zelboraf

Manufacturer/Distributor:
Hoffman-La Roche Ltd.
www.rochecanada.com 1-888-762-4388

Classification:
Protein kinase inhibitor

ATC Class:
L01XE15 - Vemurafenib

Status:
active

Notice of Compliance (yyyy/mm/dd):
2012/02/15

Date Marketed in Canada (yyyy/mm/dd):
2012/03/06

Presentation:
Tablet: 240 mg. DIN: 02380242

Comments:
Indicated as monotherapy for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. Should only be prescribed and supervised by a qualified physician experienced in the use of anti-cancer agents.

Keywords:
- vemurafenib
- melanoma

Access:
public

© 2017 BC Drug and Poison Information Centre
All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is not meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the full terms and conditions below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases.

Terms and Conditions

Source URL (retrieved on 2022-01-14 02:12): http://www.dpic.org/druglisting/vemurafenib